Form 4: Director Carrolee Barlow Reports Stock Transactions in Supernus Pharmaceuticals
SEC Form 4 Filing
Director Carrolee Barlow reports the acquisition and disposal of Supernus Pharmaceuticals common stock and restricted stock units on February 23, 2024.
Summary
- On February 23, 2024, Carrolee Barlow, a director of Supernus Pharmaceuticals, reported transactions involving the company's stock.
- Barlow acquired 3,886 shares of common stock at $0.
- Simultaneously, Barlow disposed of 3,886 restricted stock units, which vested on the same date and were settled in common stock.
- Following these transactions, Barlow beneficially owns 17,201 shares of Supernus Pharmaceuticals.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing detailing stock transactions by a company director. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.
Industry Context
Form 4 filings are standard practice and provide transparency into the trading activities of company insiders, allowing investors to gauge management's sentiment and confidence in the company's prospects.
Stakeholder Impact
- The filing provides transparency to shareholders regarding insider transactions.
- It helps stakeholders understand the alignment of interests between management and shareholders.
Key Dates
| Date | Description |
|---|---|
| 02/23/2024 | Date of stock acquisition and disposal of restricted stock units. |
| 02/27/2024 | Date of signature on the SEC filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.